2 results about "Alpha-galactosidase" patented technology

Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.

The invention relates to the technical field of microorganisms and food biology, and particularly discloses application of recombinant filamentous fungi in production of mycelium protein. The recombinant filamentous fungus provided by the invention is obtained by regulating and expressing alpha galactosidase and a mutant thereof, and has the advantages of improving the utilization efficiency of polysaccharide, improving the protein content of recombinant bacteria and accelerating the growth speed. The recombinant filamentous fungus can utilize agricultural and sideline products as a carbon source or a nitrogen source, and the fermentation mycelium protein is complete in amino acid variety, contains various essential amino acids required by human bodies, and has wide application value.